12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pimavanserin: Phase III data

Top-line data from the double-blind, North American Phase III ACP-103-020 trial in 199 patients with PDP showed that once-daily 40 mg oral pimavanserin met the primary endpoint of improving antipsychotic efficacy as measured by the mean reduction from baseline to day 43 in scores on the SAPS-PD 9-item scale vs. placebo (5.79 vs. 2.73 points, p=0.001). Pimavanserin also met the secondary endpoint of non-inferiority to placebo in maintaining motoric tolerability as measured by Parts II and III of the UPDRS from baseline to day 43. Acadia said the 95% CI for the treatment difference in UPDRS scores between treatment groups did not exceed the pre-specified non-inferiority margin of 5...

Read the full 522 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >